Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XL092 dose-escalation and expansion study in advanced solid tumors
NL-OMON52050Phase 1Not yet recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Sep 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zanzalintinib in Nonhematologic neoplasms, renal cell carcinoma (RCC), breast cancer and 3 more (4 arms), sponsored by Exelixis, Inc. Primary endpoints: Maximum tolerated dose and/or recommended dose, Objective response rate and 2 more. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
zanzalintinib
03
Conditions
Nonhematologic neoplasmsrenal cell carcinoma (RCC)breast cancerprostate cancer (PCa)colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON52050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52050.